TG THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.19 USD | +4.24% |
|
+14.43% | +12.35% |
| 06-17 | Declaration of Voting Results by TG Therapeutics | CI |
| 06-17 | Declaration of Voting Results by TG Therapeutics | CI |
Presenter SpeechUnknown Analyst (Analysts)Thanks for joining us here for the afternoon of Tues...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
19.19
USD
Average target price
31.5
USD
Spread / Average Target
+64.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.35% | 2.75B | |
| +38.36% | 52.73B | |
| +38.90% | 39B | |
| -8.63% | 38.52B | |
| +25.46% | 30.38B | |
| -11.17% | 26.39B | |
| +11.44% | 26.08B | |
| +45.09% | 14.15B | |
| +32.93% | 12.6B | |
| -5.30% | 11.51B |
- Stock Market
- Equities
- TGTX Stock
- News TG Therapeutics, Inc.
- Transcript : TG Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 01
